Boston Scientific Slides as Weak Earnings and Lower Outlook Add to Cyberattack Fallout

Boston Scientific (BSX) is down 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to a combination of softer-than-expected third-quarter profit and a reduced near-term outlook. Investors also seem focused on the lingering operational and sales disruption from the company’s previously disclosed cybersecurity incident, which is still pressuring the recovery timeline.

Details:

Boston Scientific posted third-quarter 2026 net sales of $5.138 billion, up 1.5% from a year earlier, while adjusted earnings were $0.73 per share.

The company’s fourth-quarter adjusted EPS outlook of $0.77 to $0.79 came in below market expectations, and its full-year adjusted EPS view of $3.16 to $3.18 was also lighter than investors had hoped.

Boston Scientific previously disclosed that an August 2026 cybersecurity incident disrupted certain IT systems and global operations, and it warned that the event was likely to have a material effect on 2026 results.

The updated outlook also pointed to fourth-quarter sales potentially declining year over year, reinforcing concerns that the operational disruption has not fully cleared.

Sources:

Boston Scientific, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BSX Insider Trading Activity

$BSX insiders have traded $BSX stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:

MICHAEL F MAHONEY (Chairman, President & CEO) purchased 186,240 shares for an estimated $9,001,407
EDWARD J LUDWIG has made 2 purchases buying 8,580 shares for an estimated $430,313 and 0 sales.
DAVID C HABIGER has made 5 purchases buying 7,732 shares for an estimated $407,921 and 0 sales.
SUSAN E MORANO purchased 2,040 shares for an estimated $100,407
CHERYL PEGUS purchased 1,770 shares for an estimated $99,987

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BSX Hedge Fund Activity

We have seen 742 institutional investors add shares of $BSX stock to their portfolio, and 936 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 28,523,550 shares (-38.4%) from their portfolio in Q2 2026, for an estimated $1,217,385,114
JPMORGAN CHASE & CO added 23,907,838 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,020,386,525
PRIMECAP MANAGEMENT CO/CA/ added 17,991,140 shares (+55.3%) to their portfolio in Q2 2026, for an estimated $767,861,855
D. E. SHAW & CO., INC. added 14,208,205 shares (+126.3%) to their portfolio in Q2 2026, for an estimated $606,406,189
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 13,862,619 shares (+126.1%) to their portfolio in Q2 2026, for an estimated $591,656,578
TWO SIGMA INVESTMENTS, LP added 9,947,792 shares (+105.7%) to their portfolio in Q2 2026, for an estimated $424,571,762
BANK OF AMERICA CORP /DE/ removed 9,728,863 shares (-42.8%) from their portfolio in Q2 2026, for an estimated $415,227,872

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BSX Government Contracts

We have seen $28,928,111 of award payments to $BSX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

Y90 GLASS MICROSPHERES: $1,227,000
Y90 THERASPHERE: $1,155,000
THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION: $880,000
THERASPHERE Y-90: $693,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$BSX Congressional Stock Trading

Members of Congress have traded $BSX stock 13 times in the past 6 months. Of those trades, 5 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:

REPRESENTATIVE KEVIN HERN has traded it 6 times. They made 0 purchases and 6 sales worth up to $295,000 on 09/09, 09/04, 09/03, 08/31.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 6 times. They made 5 purchases worth up to $75,000 on 08/18, 06/05, 05/29, 05/19, 05/11 and 1 sale worth up to $15,000 on 06/05.
SENATOR JOHN BOOZMAN sold up to $15,000 on 06/04.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BSX Analyst Ratings

Wall Street analysts have issued reports on $BSX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/03/2026

To track analyst ratings and price targets for $BSX, check out Quiver Quantitative's $BSX forecast page.

$BSX Price Targets

Multiple analysts have issued price targets for $BSX recently. We have seen 13 analysts offer price targets for $BSX in the last 6 months, with a median target of $67.0.

Here are some recent targets:

Mike Matson from Needham set a target price of $57.0 on 07/08/2026
Vijay Kumar from Evercore ISI Group set a target price of $65.0 on 07/06/2026
Rick Wise from Stifel set a target price of $65.0 on 06/25/2026
Matthew Taylor from Jefferies set a target price of $67.0 on 06/24/2026
Marie Thibault from BTIG set a target price of $65.0 on 06/16/2026
Richard Newitter from Truist Securities set a target price of $64.0 on 06/04/2026
William Plovanic from Canaccord Genuity set a target price of $70.0 on 06/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.